Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00107718 · ClinicalTrials.gov registry record · Phase 2
Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma
A Phase 2 study of Melanoma, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 20
- Study locations
NCT00107718 is a Phase 2 study of Melanoma that has completed, run by GlaxoSmithKline. The registered enrollment target is 64 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT00107718, a Phase 2 study of Melanoma, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic melanoma.
Conditions Studied
Interventions
- DRUG SB-485232
Study Locations (20)
California
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - San Francisco
- GSK Investigational Site - Santa Monica
Queensland
- GSK Investigational Site - Douglas
- GSK Investigational Site - South Brisbane
- GSK Investigational Site - Woolloongabba
Florida
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - Miami Beach
New South Wales
- GSK Investigational Site - Waratah
- GSK Investigational Site - Westmead
Connecticut
- GSK Investigational Site - New Haven
Illinois
- GSK Investigational Site - Chicago
Indiana
- GSK Investigational Site - Indianapolis
Maryland
- GSK Investigational Site - Lutherville-Timonium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2004-11-15 |
| Est. Completion | 2006-05-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00107718
The ClinicalTrials.gov registry entry for NCT00107718 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which SB-485232 is the first listed.
NCT00107718 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Queensland, Florida.
Frequently Asked Questions
What is clinical trial NCT00107718 about?
NCT00107718 is a clinical study titled "Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma". This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic melanoma.
What is the current status of trial NCT00107718?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2004-11-15. Estimated completion is 2006-05-19.
What conditions does trial NCT00107718 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00107718?
The interventions under investigation include: SB-485232 (DRUG).
Who is sponsoring clinical trial NCT00107718?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00107718 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.